Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Rueda

Showing results (71-80 of 220) with videos related to

Pageof 22
Sort By:
Cancer Drug Resistance (Alhambra, Calif.)|July 17, 2023
The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancerSara Bouberhan, Liron Bar-Peled, Yusuke Matoba, et al.
Journal of Ovarian Research|November 5, 2014
Notch signaling in serous ovarian cancerJolijn W Groeneweg, Rosemary Foster, Whitfield B Growdon, et al.
Endocrine|August 30, 2000
Putative role of the phosphatidylinositol 3-kinase-Akt signaling pathway in the survival of granulosa cellsS D Westfall, I R Hendry, K L Obholz, et al.
Gynecologic Oncology|October 19, 2001
Endometrial cancer in women 40 years old or youngerL R Duska, A Garrett, B R Rueda, et al.
Biology of Reproduction|February 1, 1995
Internucleosomal DNA fragmentation in ovine luteal tissue associated with luteolysis: in vivo and in vitro analysesB R Rueda, J A Wegner, S L Marion, et al.
Cancers|November 2, 2019
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem CellsChiara Bellio, Celeste DiGloria, David R Spriggs, et al.
Endocrine|December 15, 2010
Comparison of mRNA levels for the PGF(2α) receptor (FP) during luteolysis and early pregnancy in the ovine corpus luteumB R Rueda, I W Botros, K L Pierce, et al.
Endocrine|December 15, 2010
Expression of superoxide dismutase, catalase and glutathione peroxidase in the bovine corpus luteum: evidence supporting a role for oxidative stress in luteolysisB R Rueda, K I Tilly, T R Hansen, et al.
Cancers|June 4, 2020
Galectins and Ovarian CancerChisa Shimada, Rui Xu, Linah Al-Alem, et al.
Gynecologic Oncology|March 29, 2016
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutationSilvia F Hernandez, Sarah Chisholm, Darrell Borger, et al.
Pageof 22

Showing results (71-80 of 220) with videos related to

Sort By:
Pageof 22
Cancer Drug Resistance (Alhambra, Calif.)|July 17, 2023
The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancerSara Bouberhan, Liron Bar-Peled, Yusuke Matoba, et al.
Journal of Ovarian Research|November 5, 2014
Notch signaling in serous ovarian cancerJolijn W Groeneweg, Rosemary Foster, Whitfield B Growdon, et al.
Endocrine|August 30, 2000
Putative role of the phosphatidylinositol 3-kinase-Akt signaling pathway in the survival of granulosa cellsS D Westfall, I R Hendry, K L Obholz, et al.
Gynecologic Oncology|October 19, 2001
Endometrial cancer in women 40 years old or youngerL R Duska, A Garrett, B R Rueda, et al.
Biology of Reproduction|February 1, 1995
Internucleosomal DNA fragmentation in ovine luteal tissue associated with luteolysis: in vivo and in vitro analysesB R Rueda, J A Wegner, S L Marion, et al.
Cancers|November 2, 2019
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem CellsChiara Bellio, Celeste DiGloria, David R Spriggs, et al.
Endocrine|December 15, 2010
Comparison of mRNA levels for the PGF(2α) receptor (FP) during luteolysis and early pregnancy in the ovine corpus luteumB R Rueda, I W Botros, K L Pierce, et al.
Endocrine|December 15, 2010
Expression of superoxide dismutase, catalase and glutathione peroxidase in the bovine corpus luteum: evidence supporting a role for oxidative stress in luteolysisB R Rueda, K I Tilly, T R Hansen, et al.
Cancers|June 4, 2020
Galectins and Ovarian CancerChisa Shimada, Rui Xu, Linah Al-Alem, et al.
Gynecologic Oncology|March 29, 2016
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutationSilvia F Hernandez, Sarah Chisholm, Darrell Borger, et al.
Pageof 22